NCT03815344 · STUDY IN CONTEXT

Combined Vaginal Misoprostol and Perivascular Vasopressin

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The difference in hemoglobin levels between pre surgery and post surgery

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-myoma
nct id: NCT03815344
trial label: Combined Vaginal Misoprostol and Perivascular Vasopressin
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-myoma
nct id
NCT03815344
outcome key
om-0000
source section id
NCT03815344-om-0000
source outcome index
0
endpoint
Hemoglobin Levels Difference Between Pre and Post Surgery.
endpoint definition
The difference in hemoglobin levels between pre surgery and post surgery
time origin
1 hour
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-myoma
nct id
NCT03815344
outcome key
om-0000
arm key
OG000
arm label
Standard
regimen
Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. Standard-vaginal misoprostol: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03815344-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-myoma
nct id
NCT03815344
outcome key
om-0000
arm key
OG001
arm label
Standard-Vaginal Misoprostol
regimen
Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement . Standard: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle Standard-vaginal misoprostol: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
analyzed count
32
analyzed unit
Participants
is comparator
Source null
source pointer
NCT03815344-om-0000#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-myoma
nct id
NCT03815344
harm key
EG000
source section id
NCT03815344-ae
event group key
EG000
event group label
Standard
serious affected
0
serious at risk
42
other affected
0
other at risk
42
frequency threshold
0
collection period
1 hour post surgery
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-myoma
nct id
NCT03815344
harm key
EG001
source section id
NCT03815344-ae
event group key
EG001
event group label
Standard-Vaginal Misoprostol
serious affected
0
serious at risk
32
other affected
0
other at risk
32
frequency threshold
0
collection period
1 hour post surgery
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice